For example, X-ray and NMR were used to discover a potent and selective allosteric ABL1 tyrosine kinase inhibitor that is undergoing clinical development testing in patients with leukaemia [2], and NMR-based screening and SBDD were used to discover a BCL-2 inhibitor that is undergoing clinical trials in lymphomas, leukemia, and myeloma [3]. The gene discussed is BCL2; the disease is leukemia.